|

Zanzalintinib Clinical Trials

20 actively recruiting trials across 12 locations

▲ +2 trials since June 2026

Also known as: Multi-kinase Inhibitor XL092, XL 092, XL-092, XL092

Pipeline

Phase 1: 6Phase 2: 8Phase 3: 2Phase 1/2: 3Phase 2/3: 1

Top Sponsors

  • Washington University School of Medicine4
  • Exelixis4
  • Merck Sharp & Dohme LLC3
  • M.D. Anderson Cancer Center3
  • University of Chicago1

Indications

San Francisco, California3 trials

A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

Exelixis Clinical Site #5

Phase 1
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

UCSF Medical Center at Mission Bay ( Site 5008)

Phase 1/2
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

University of California, San Francisco

Phase 1

Chicago, Illinois3 trials

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

University of Chicago Medicine Comprehensive Cancer Center

Phase 1
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma

Northwestern University

Phase 2
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

Northwestern University

Phase 1/2

Birmingham, Alabama2 trials

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

University of Alabama

Phase 2
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

The University of Alabama at Birmingham

Phase 2/3

St Louis, Missouri2 trials

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Washington University School of Medicine

Phase 1
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

Washington University School of Medicine

Phase 1

Houston, Texas2 trials

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

The University of Texas M. D. Anderson Cancer Center

Phase 2
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

MD Anderson Cancer Center

Phase 2

Other1 trial

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Phase 3

Anchorage, Alaska1 trial

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Alaska Oncology and Hematology ( Site 0133)

Phase 3

Phoenix, Arizona1 trial

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Exelixis Clinical Site #67

Phase 1

Torrance, California1 trial

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

Harbor-UCLA Medical Center

Phase 2

Indianapolis, Indiana1 trial

Maintenance Zanzalintinib With Etoposide After HDCT in GCT

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Phase 1/2

Rochester, Minnesota1 trial

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

Mayo Clinic - Rochester

Phase 2

Cleveland, Ohio1 trial

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Cleveland Clinic Taussig Cancer Institute

Phase 2

Pittsburgh, Pennsylvania1 trial

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

UPMC Hillman Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.